ライフサイエンスコーパス: parathyroid hormone

1 ts increase is associated with a decrease in parathyroid hormone.

2 (receptor activator of NFkappaB ligand) and parathyroid hormone.

3 There was no effect modification by parathyroid hormone.

4 nd action of fibroblast growth factor 23 and parathyroid hormone.

5 blood pressure or arterial pressure and with parathyroid hormone.

6 ndoxyl sulfate, homocysteine, uric acid, and parathyroid hormone.

7 cluding carboxymethyllysine, cystatin C, and parathyroid hormone.

8 or inappropriately normal concentrations of parathyroid hormone.

9 er characterized by autonomous production of parathyroid hormone.

10 The parathyroid hormone 1 receptor (PTHR) is central to the

11 In another study, we showed that parathyroid hormone 1-34 and anti-sclerostin antibody at

12 tolerability of once-daily recombinant human parathyroid hormone 1-84 (rhPTH[1-84]) in adults with hy

13 Studies by Sato et al. reveal a role for parathyroid hormone 2 receptor (PTH2R) in extracellular

14 f 39 residues (TIP39), via its receptor, the parathyroid hormone 2 receptor (PTH2R), modulates fear m

15 Small interfering RNA-mediated silencing of parathyroid hormone 2 receptor (PTH2R), the receptor for

16 hese areas are enriched in its receptor, the parathyroid hormone 2 receptor (PTH2R).

17 e of 39 residues (TIP39) is a ligand for the parathyroid hormone 2 receptor (PTH2R).

18 hosphorus, alkaline phosphatase, creatinine, parathyroid hormone, 25 hydroxy vitamin D3 and 1, 25 dih

19 racteristics, dietary intakes, fasting serum parathyroid hormone, 25-hydroxyvitamin D [25(OH)D], and

20 Parathyroid hormone, 25-hydroxyvitamin D, liver function

21 ge mean+/-SD single-pass renal extraction of parathyroid hormone (44.2%+/-10.3%) that exceeded the ex

22 hyperparathyroidism (median level of intact parathyroid hormone, 693 pg per milliliter [10th to 90th

23 0.09 mmol/L, 95% CI 0.02-0.17, p=0.009), and parathyroid hormone (+7.32 pg/mL, 3.42-11.23, p<0.0001).

24 Parathyroid hormone, a potentially modifiable biological

25 Parathyroid hormone above the upper limit of normal (65

26 Increases in serum parathyroid hormone accompanied skeletal healing, often

27 (CV) system, including increasing levels of parathyroid hormone, activating the renin-angiotensin-al

28 signature of the arrestin pathway-selective parathyroid hormone analog [d-Trp(12), Tyr(34)]bovine PT

29 The cAMP response induced by M-PTH(1-14), a parathyroid hormone analog, terminated quickly in HEK293

30 Serum concentrations of intact parathyroid hormone and bone-specific alkaline phosphata

31 growth factor-1 and high, but not low, dose parathyroid hormone and exogenous Wnt-3a.

32 albumin and inversely associated with serum parathyroid hormone and ferritin.

33 in chronic kidney disease and the effects of parathyroid hormone and FGF23 on these associations.

34 ant role for vitamin D and related hormones, parathyroid hormone and fibroblast growth factor 23 (FGF

35 splant patients significantly reduced intact parathyroid hormone and increased fibroblast growth fact

36 of 1alpha-hydroxylase but not with levels of parathyroid hormone and of 24-hydroxylase.

37 -dihydroxyvitamin D (1,25(OH)2D), FGF23, and parathyroid hormone and performed quantitative echocardi

38 iates the endocrine and paracrine effects of parathyroid hormone and related peptides through the act

39 Paricalcitol decreases intact parathyroid hormone and the frequency of secondary hyper

40 alphas also inhibited internalization of the parathyroid hormone and type 2 vasopressin receptors.

41 rations <20 ng/mL who did not also have high parathyroid hormone and women with high parathyroid horm

42 luding C-terminal fragment of FGF-23, intact parathyroid hormone, and 1,25(OH)(2)D(3), were measured

43 Maternal 25(OH)D, parathyroid hormone, and 1,25-dihydroxyvitamin D [1,25(O

44 ulated by numerous factors, including BMP-2, parathyroid hormone, and 1alpha,25-dihydroxyvitamin D3 (

45 ium, phosphorus, 25-hydroxyvitamin D, intact parathyroid hormone, and 24,25-dihydroxyvitamin D did no

46 In contrast, serum calcium, parathyroid hormone, and 25-hydroxyvitamin D concentrati

47 measured serum levels of phosphate, calcium, parathyroid hormone, and 25-hydroxyvitamin D in 1,938 Ca

48 use of monoclonal or polyclonal antibodies), parathyroid hormone, and albumin.

49 n D, 1,25-dihydroxyvitamin D [1,25(OH)(2)D], parathyroid hormone, and calcium intake were evaluated.

50 ong hormones, including 1,25(OH)2D3 (1,25D), parathyroid hormone, and fibroblast growth factor 23 (FG

51 including serum levels of 25(OH) vitamin D, parathyroid hormone, and fibroblast growth factor 23.

52 eomalacia, hypophosphatemia, increased serum parathyroid hormone, and increased levels of the phospha

53 ar, serum osteocalcin, total calcium, intact parathyroid hormone, and increased serum C telopeptide.

54 to determine changes in calcium, phosphorus, parathyroid hormone, and serum creatinine.

55 s with dissociable agonists for thyrotropin, parathyroid hormone, and sphingosine-1-phosphate were fo

56 plasma levels of FGF23, calcium, phosphate, parathyroid hormone, and vitamin D metabolites.

57 ffect on basal bone resorption, it inhibited parathyroid hormone- and ovariectomy-induced OC activati

58 er levels of serum calcium, phosphorous, and parathyroid hormone; and nutritional vitamin D, cinacalc

59 terminal propeptide (PINP), osteocalcin, and parathyroid hormone as well as a transient decrease in t

60 oxyvitamin D, vitamin D-binding protein, and parathyroid hormone as well as bone mineral density (BMD

61 substantial single-pass renal extraction of parathyroid hormone at a rate that exceeds glomerular fi

62 hly expressed in osteocytes, is regulated by parathyroid hormone both in vitro and in vivo, and prote

63 FGF23, despite having high concentrations of parathyroid hormone, but administration of exogenous 1,2

64 evels, serum calcium homeostasis biomarkers (parathyroid hormone, calcium, and 25-hydroxyvitamin D),

65 relationships), yet within each quintile of parathyroid hormone concentration, blacks had significan

66 espectively; P=0.71) and within quintiles of parathyroid hormone concentration.

67 whether lower 25-hydroxyvitamin D and higher parathyroid hormone concentrations are associated with i

68 sis did not have major effects on calcium or parathyroid hormone concentrations in either trial.

69 turic response occurred after plasma PO4 and parathyroid hormone concentrations increased.

70 Higher serum parathyroid hormone concentrations showed a significant,

71 intervals (CIs) for 25-hydroxyvitamin D and parathyroid hormone concentrations with incident hyperte

72 perparathyroidism, and might be predicted by parathyroid hormone concentrations, even in individuals

73 KO and WT mice had similar serum calcium and parathyroid hormone concentrations.

74 tein 3 but lower 1,25-dihydroxyvitamin D and parathyroid hormone concentrations.

75 The proportionate renal extraction of parathyroid hormone correlated with eGFR.

76 operative success, defined by intraoperative parathyroid hormone criteria, and complication rates wer

77 mg/dL (95% confidence interval, 0.28-0.64), parathyroid hormone decreased by 102 pg/mL (95% confiden

78 Intact parathyroid hormone decreased in paricalcitol-treated pa

79 Parathyroid hormone decreased NHE3 surface expression, b

80 anges in serum calcium, phosphate, or intact parathyroid hormone during the study.

81 th the use of dual-stable isotopes, 25(OH)D, parathyroid hormone, estradiol, calcitriol, and urinary

82 a common endocrine disease characterized by parathyroid hormone excess and hypercalcemia and caused

83 etermined the single-pass renal clearance of parathyroid hormone, fibroblast growth factor 23, vitami

84 /- 10.3 ng/mL; P < 0.0001) and a decrease in parathyroid hormone (from 21.4 +/- 10.4 to 12.9 +/- 7.1

85 splantation, persistent hyperparathyroidism (parathyroid hormone > 130 ng/L) and bone turnover marker

86 s with secondary hyperparathyroidism (intact parathyroid hormone >/=300 pg/mL).

87 Compared with parathyroid hormone <33 pg/ml, parathyroid hormone >/=65 pg/ml was associated with a si

88 th low urine output, low serum albumin, high parathyroid hormone, high ferritin, and the use of bioin

89 de (Oct), salmon calcitonin (sCT), and human parathyroid hormone (hPTH) was evaluated.

90 Intermittent Parathyroid Hormone (I-PTH) is the only FDA approved ana

91 at 1000 IU/d increases 25(OH)D and decreases parathyroid hormone in children with average vitamin D i

92 The endocrine and bone anabolic agent parathyroid hormone increased specialized proresolving m

93 Levels of parathyroid hormone increased with decreasing levels of

94 ctions in secondary HPT, including decreased parathyroid hormone, increased vitamin D, increased seru

95 der these circumstances both agents enhanced parathyroid hormone-induced osteoblast differentiation a

96 Intraoperative parathyroid hormone (IoPTH) monitoring has enabled surge

97 rmine whether to wait for the intraoperative parathyroid hormone (ioPTH) or to explore further.

98 ients with hypercalcemia and elevated intact parathyroid hormone (iPTH) concentration were eligible i

99 Intermittent parathyroid hormone (iPTH) treatment expands hemopoietic

100 Intermittent parathyroid hormone (iPTH) treatment stimulates T-cell p

101 omes measures included serum calcium, intact parathyroid hormone (iPTH), and thyroid stimulating horm

102 ium concentration is within normal range but parathyroid hormone is elevated in the absence of any ob

103 aemia caused by autonomous overproduction of parathyroid hormone, is common, especially in postmenopa

104 x, and creatinine clearance, but with intact parathyroid hormone less than 100 pg/mL, were included a

105 ltiply by 0.25; P = .15), preoperative serum parathyroid hormone level (mean [SD], 114.5 [56.8] vs 13

106 rogression were age, baseline total or whole parathyroid hormone level greater than nine times the no

107 Regarding modifiable factors, higher average parathyroid hormone level was associated with greater ri

108 walking, and higher average log-transformed parathyroid hormone level were independently associated

109 ent risk was attenuated after adjustment for parathyroid hormone level, suggesting that parathyroid h

110 sphatemia and hypomagnesemia with low plasma parathyroid hormone level.

111 Patients on HD with intact parathyroid hormone levels </=300 pg/ml receiving dialys

112 nover in patients on HD with baseline intact parathyroid hormone levels </=300 pg/ml.

113 ncreased sessional dialysis dose and lowered parathyroid hormone levels (from 51 +/- 67 to 24 +/- 37

114 ficiency at day 7 having significantly lower parathyroid hormone levels (p<0.01).

115 lerated) or nonparicalcitol therapy on serum parathyroid hormone levels (primary outcome), mineral me

116 itamin D receptor activator, decreased serum parathyroid hormone levels and proteinuria in patients w

117 6-month paricalcitol supplementation reduced parathyroid hormone levels and proteinuria, attenuated b

118 Parathyroid hormone levels at 12 months decreased with a

119 Parathyroid hormone levels decreased over the study peri

120 s induced by aldosteronism in which elevated parathyroid hormone levels raise the risk of adverse car

121 baseline, median (interquartile range) serum parathyroid hormone levels significantly declined on par

122 dihydroxyvitamin D(3) levels were normal but parathyroid hormone levels were decreased.

123 lcium, phosphorus, alkaline phosphatase, and parathyroid hormone levels were determined.

124 Median intact parathyroid hormone levels were lower and severe hyperpa

125 Treatment with paricalcitol reduced parathyroid hormone levels within 4 weeks and maintained

126 mice had significantly lower serum FGF23 and parathyroid hormone levels, and higher renal 1-alpha-hyd

127 irmed by exploratory surgery, intraoperative parathyroid hormone levels, and pathologic features.

128 by increased serum 1,25-(OH)2-vitamin D3 and parathyroid hormone levels, decreased serum calcium leve

129 response or a hormonal response to decreased parathyroid hormone levels, we subjected osteocytes to a

130 ents also displayed higher plasma FGF-23 and parathyroid hormone levels.

131 l function, or preoperative serum calcium or parathyroid hormone levels.

132 ocorticoid exposure and greater decreases in parathyroid hormone levels.

133 In this study, we report that TIP39, a parathyroid hormone ligand family member that was recent

134 translocations caused downregulation of the parathyroid hormone-like hormone (PTHLH) gene by disrupt

135 Parathyroid hormone-like hormone (Pthlh) inhibits hypert

136 5 (Gdf5), the transcription factor Erg, and parathyroid hormone-like hormone (Pthlh), and selection

137 orylation and TGF-beta-induced expression of parathyroid hormone-like hormone (PTHLH), leading to ost

138 stric mucosal neuroendocrine cells including parathyroid hormone-like hormone in histamine-secreting

139 , and Ihh target genes Patched 1 (Ptch1) and parathyroid hormone-like peptide (Pthlh) were down-regul

140 Pth4, an ancient parathyroid hormone lost in eutherian mammals, reveals a

141 Compared with parathyroid hormone <33 pg/ml, parathyroid hormone >/=65

142 Impaired renal clearance of parathyroid hormone may contribute to secondary hyperpar

143 r parathyroid hormone level, suggesting that parathyroid hormone may mediate this association.

144 asive parathyroidectomy using intraoperative parathyroid hormone monitoring remains the standard appr

145 y invasive parathyroidectomy, intraoperative parathyroid hormone monitoring via a reliable protocol i

146 affect existing criteria for intraoperative parathyroid hormone monitoring.

147 In parathyroid hormone or 1alpha,25(OH)2-vitamin D3 (D3)-st

148 strogen deficiency and sustained exposure to parathyroid hormone or RANKL.

149 ccurred in serum calcium, phosphorus, intact parathyroid hormone, or C-reactive protein levels, cinac

150 not be explained by hypocalcemia, changes in parathyroid hormone, or fibroblast growth factor 23.

151 , levels of calcium, phosphorus, calcitriol, parathyroid hormone, or fibroblast growth factor-23 were

152 not explained by urine phosphate excretion, parathyroid hormone, or fibroblast growth factor-23.

153 e-colony stimulating factor, growth hormone, parathyroid hormone, or stem cell factor each stimulates

154 citol treatment significantly reduced intact parathyroid hormone (P<0.001) and alkaline phosphatase (

155 etabolic pathway (e.g., 25-hydroxyvitamin D, parathyroid hormone, phosphorus) had little impact.

156 nine, free thyroxine, free triiodothyronine, parathyroid hormone, prolactin, N-terminal pro-brain nat

157 um metabolism was defined as elevated intact parathyroid hormone (PTH) (>62 pg/mL) accompanied by a v

158 Parathyroid hormone (PTH) activates receptors on osteocy

159 Intermittent parathyroid hormone (PTH) administration increases syste

160 cium through processes that are regulated by parathyroid hormone (PTH) and 1alpha,25-dihydroxyvitamin

161 Parathyroid hormone (PTH) and calcium levels, recurrent

162 Parathyroid hormone (PTH) and FGF23 are the primary horm

163 Parathyroid hormone (PTH) and fibroblast growth factor 2

164 echanisms through which Pi intake stimulates parathyroid hormone (PTH) and fibroblast growth factor-2

165 a was associated with low FGF23 despite high parathyroid hormone (PTH) and high calcitriol levels.

166 Parathyroid hormone (PTH) and the sympathetic tone promo

167 The bone catabolic actions of parathyroid hormone (PTH) are seen in patients with hype

168 Continuous parathyroid hormone (PTH) blocks its own osteogenic acti

169 Previously, we have shown that intermittent parathyroid hormone (PTH) bone anabolic therapy involves

170 3 patients receiving hemodialysis with serum parathyroid hormone (PTH) concentrations higher than 500

171 ravenous calcimimetic etelcalcetide on serum parathyroid hormone (PTH) concentrations in patients rec

172 ciations of 25-hydroxyvitamin D (25-OHD) and parathyroid hormone (PTH) concentrations separately and

173 dc73(+/-) mice also had increased mean serum parathyroid hormone (PTH) concentrations.

174 Intermittent administration of parathyroid hormone (PTH) dramatically increases bone ma

175 ], 1,25-dihydroxyvitamin D [1,25(OH)2D], and parathyroid hormone (PTH) in maternal circulation and co

176 he PT-Dicer(-/-) mice did not increase serum parathyroid hormone (PTH) in response to acute hypocalce

177 Parathyroid hormone (PTH) induces osteoclast formation a

178 Genes related to the parathyroid hormone (PTH) influence cutaneous immune def

179 Parathyroid hormone (PTH) is a primary calcium regulator

180 Parathyroid hormone (PTH) is an important regulator of o

181 Parathyroid hormone (PTH) is known for its ability to 'b

182 Parathyroid hormone (PTH) is recognized to be an importa

183 Parathyroid hormone (PTH) is the only current anabolic t

184 Parathyroid hormone (PTH) is the only Food and Drug Admi

185 yroidism is characterized by increased serum parathyroid hormone (PTH) level and parathyroid cell pro

186 ce and impact of HPT, defined as an elevated parathyroid hormone (PTH) level, after renal transplanta

187 Serum calcium level, parathyroid hormone (PTH) level, and femur and spine BMD

188 CFR was inversely related to parathyroid hormone (PTH) levels (r=-0.3, P<0.004).

189 ibited reduced serum inorganic phosphate and parathyroid hormone (PTH) levels and decreased bone form

190 nvestigated the association between baseline parathyroid hormone (PTH) levels and major cardiovascula

191 tionship between endothelial dysfunction and parathyroid hormone (PTH) levels in RTRs has been demons

192 pocalcemia, measurement of serum calcium and parathyroid hormone (PTH) levels, and algorithms for sup

193 l quantitative computed tomography (HRpQCT), parathyroid hormone (PTH) levels, and bone turnover mark

194 us metabolism, including serum phosphate and parathyroid hormone (PTH) levels, did not consistently a

195 ned assessment of 25-OH-D with its regulator parathyroid hormone (PTH) may be required for optimal ev

196 em cells (HSCs) is induced by treatment with parathyroid hormone (PTH) or activation of the PTH recep

197 ia, anti-KRN23 antibodies, or elevated serum parathyroid hormone (PTH) or creatinine.

198 Parathyroid hormone (PTH) orchestrates the signaling of

199 isciplinary analytical characterization of a parathyroid hormone (PTH) peptide active pharmaceutical

200 Intermittent administration of parathyroid hormone (PTH) promotes new bone formation in

201 Agonist-induced phosphorylation of the parathyroid hormone (PTH) receptor 1 (PTHR1) regulates r

202 osteoblastic cell-specific activation of the parathyroid hormone (PTH) receptor attenuates BCR-ABL1 o

203 alloproteinase-13 (MMP-13) transcription and parathyroid hormone (PTH) regulates HDAC4 to control MMP

204 Ib(delNASm)), a disorder of proximal tubular parathyroid hormone (PTH) resistance associated with los

205 PRG4 was identified as a novel parathyroid hormone (PTH) responsiveness gene in osteobl

206 aR) modulates renal calcium reabsorption and parathyroid hormone (PTH) secretion and is involved in t

207 ition of the abundant let-7 family increased parathyroid hormone (PTH) secretion in normal and uremic

208 , whether they had any functional effects on parathyroid hormone (PTH) secretion in parathyroid neopl

209 in D receptor agonists are known to suppress parathyroid hormone (PTH) secretion.

210 ls blood calcium concentration by regulating parathyroid hormone (PTH) secretion.

211 CLA treatment increased serum parathyroid hormone (PTH) significantly (p=0.0172), whil

212 Upon parathyroid hormone (PTH) stimulation, the PTHR internal

213 e typically on either oral bisphosphonate or parathyroid hormone (PTH) therapy.

214 absence of ascorbate and were stimulated by parathyroid hormone (PTH) to undergo rapid osteoclast fo

215 Intermittent parathyroid hormone (PTH) treatment is well established

216 -coupled receptor agonists (isoproterenol or parathyroid hormone (PTH)(1-34)).

217 A complex feedback mechanism between parathyroid hormone (PTH), 1,25(OH)2D3 (1,25D), and fibr

218 was the primary outcome, and serum calcium, parathyroid hormone (PTH), 1,25-dihydroxyvitamin D [1,25

219 ogenesis, confluent BMSCs were cultured with parathyroid hormone (PTH), 1,25-dihydroxyvitamin D3 (1,2

220 In response to parathyroid hormone (PTH), a bone anabolic hormone, LepR

221 Human parathyroid hormone (PTH), a member of class B GPCRs, bi

222 on tubular reabsorption of phosphate (TRP), parathyroid hormone (PTH), bone alkaline phosphatase (BA

223 xamined the prospective associations between parathyroid hormone (PTH), circulating 25-hydroxyvitamin

224 parathyroid chief and oxyphil cells produce parathyroid hormone (PTH), express the calcium-sensing r

225 ercalcemic patients underwent measurement of parathyroid hormone (PTH), had documentation of hypercal

226 Teriparatide, a recombinant form of parathyroid hormone (PTH), is the only approved treatmen

227 transferrin saturation (TSAT) concentration, parathyroid hormone (PTH), IV vitamin D dose, cinacalcet

228 ata defined by their pretransplant levels of parathyroid hormone (PTH), low PTH (>65 to </=300 pg/mL;

229 ALN, parathyroid hormone (PTH), or saline (vehicle control) w

230 enes involved in signaling through Wnt, FSH, parathyroid hormone (PTH), oxytocin, and calcineurin/nuc

231 vels of fibroblast growth factor-23 (FGF23), parathyroid hormone (PTH), phosphate, and 25-hydroxyvita

232 nd their determinants, including circulating parathyroid hormone (PTH), total alkaline phosphatase ac

233 over and pronounced osteoblast resistance to parathyroid hormone (PTH), which is indicated by decreas

234 itory effects of TCN on lipopolysaccharide-, parathyroid hormone (PTH)-, and prostaglandin E2 (PGE2)-

235 al to Cyp27b1 that mediates unique basal and parathyroid hormone (PTH)-, fibroblast growth factor 23

236 nique role of osteal macrophages in bone and parathyroid hormone (PTH)-dependent bone anabolism using

237 urinary calcium excretion in the context of parathyroid hormone (PTH)-dependent hypercalcemia, but t

238 In the kidney, these mutations interrupt parathyroid hormone (PTH)-responsive sequestration of th

239 m baseline in blood and urine markers of the parathyroid hormone (PTH)-vitamin D-fibroblast growth fa

240 f preoperative serum calcium by preoperative parathyroid hormone (PTH).

241 ts in response to mechanical stimulation and parathyroid hormone (PTH).

242 oncentration >/=30 ng/mL) and decrease serum parathyroid hormone (PTH).

243 a constitutively activating mutation of the parathyroid hormone (PTH)/PTH-related protein (PTHrP) re

244 e anabolism through direct activation of the parathyroid hormone (PTH)/PTH-related protein receptor (

245 ostasis and is tightly regulated through the parathyroid hormone (PTH)/PTHrP receptor (PTH1R) signali

246 We reveal the existence of an ancient parathyroid hormone (Pth)4 in zebrafish that was seconda

247 Parathyroid hormone (PTH, 84 residues) and PTH-related p

248 Synthetic parathyroid hormone [PTH(1-34)] has been investigated fo

249 The parathyroid hormone receptor (PTHR) is a class B G prote

250 The G protein-coupled parathyroid hormone receptor (PTHR) regulates mineral-io

251 The parathyroid hormone receptor (PTHR), type II sodium-depe

252 The parathyroid hormone receptor (PTHR), which regulates min

253 The parathyroid hormone receptor 1 (PTHR1) is a member of th

254 However, parathyroid hormone receptor type 1 (PTHR), an essential

255 Together with recent work on the parathyroid hormone receptor, these data support the exi

256 Using an agonist of parathyroid hormone receptor-1 (PTHR1), a G protein-coup

257 tain interacting partners such as Lfc or the parathyroid hormone receptor.

258 sensitive radioimmunoassay to measure serum parathyroid hormone-related peptide (PTHrP) and a mouse

259 The majority of cells expressing parathyroid hormone-related peptide (PTHrP) are in the d

260 Parathyroid hormone-related peptide (PTHrP) is recognize

261 pression in chondrocytes strictly depends on parathyroid hormone-related peptide (PTHrP) signaling pa

262 r translocation of Gli2 and transcription of parathyroid hormone-related peptide (PTHrP), a key regul

263 st and prostate cancer metastasis biomarker, parathyroid hormone-related peptide (PTHrP).

264 ATDC5 chondrogenic cells is downregulated by parathyroid hormone-related peptide through transcriptio

265 targets (plasminogen activator inhibitor-1, parathyroid hormone-related peptide, connective tissue g

266 ix protein 1, a direct targeting molecule of parathyroid hormone-related peptide, negatively regulate

267 Parathyroid hormone-related protein (PTHrP) contributes

268 K14-PTHrP transgenic mice [which overexpress parathyroid hormone-related protein (PTHrP) in their dev

269 Parathyroid hormone-related protein (PTHrP) is a critica

270 Parathyroid hormone-related protein (PTHrP) is produced

271 Here we addressed the hypothesis that the parathyroid hormone-related protein (PTHrP) potentiates

272 Parathyroid hormone-related protein (PTHrP) regulates ce

273 Parathyroid hormone-related protein (PTHrP) regulates th

274 Increased levels of parathyroid hormone-related protein (PTHrP), known to in

275 egulates endochondral ossification in both a parathyroid hormone-related protein (PTHrP)-dependent an

276 ivation, increased Indian hedgehog (Ihh) and parathyroid hormone-related protein (Pthrp, also known a

277 as been made in determining the roles of the parathyroid hormone-related protein, Indian hedgehog, fi

278 or the quantification of a cancer biomarker (parathyroid hormone-related protein, PTHrP) in a real cl

279 sis in the absence of the receptor (PPR) for parathyroid hormone-related protein.

280 cancer cachexia, we show that tumour-derived parathyroid-hormone-related protein (PTHrP) has an impor

281 Median serum intact parathyroid hormone remained stable with active therapy

282 een the groups, patients who did not mount a parathyroid hormone response to vitamin D deficiency had

283 nthracenyl-terpyridine as a modulator of the parathyroid hormone response.

284 as phosphates, fibroblast growth factor 23, parathyroid hormone, sclerostin, or vitamin D and their

285 roblast growth factor (FGF-2)-knockout mice, parathyroid hormone stimulation and myeloablative treatm

286 fecal fat excretion, macronutrient use, and parathyroid hormone suppression.

287 ed increases (P <0.01) in postprandial serum parathyroid hormone suppression.

288 ndomized to receive 20 mug recombinant human parathyroid hormone (teriparatide) or placebo for 18 mon

289 ositively by 1,25(OH)2D3, retinoic acid, and parathyroid hormone through both intergenic and intronic

290 Parathyroid-hormone-type 1 receptor (PTH1R) is extensive

291 e rotation was associated with the change in parathyroid hormone values (r=0.37, P=0.02) and to the c

292 calcium, phosphate, 25-hydroxyvitamin D, and parathyroid hormone), various inflammatory markers (C-re

293 xyvitamin D was 26.3 +/- 11.2 ng/ml and mean parathyroid hormone was 41.2 +/- 17.3 pg/ml.

294 Intact parathyroid hormone was related to higher systolic and d

295 nal 25-hydroxyvitamin D [25(OH)D] and intact parathyroid hormone were measured at entry to care (mean

296 Serum 25-hydroxyvitamin D and intact parathyroid hormone were measured from previously frozen

297 Normal serum phosphate and parathyroid hormone were observed in HMWKO mice.

298 is defined by a high concentration of intact parathyroid hormone when circulating 25-hydroxyvitamin D

299 high parathyroid hormone and women with high parathyroid hormone whose 25(OH)D concentrations were >2

300 actor 23 was, on average, lower than that of parathyroid hormone with greater variability across indi